CSTL: TissueCypher and DecisionDx tests drive growth, with AI and reimbursement advances supporting expansion
Strong growth in molecular diagnostics, especially TissueCypher, is supported by robust margins and AI-driven innovation. Dermatology and gastroenterology segments are expanding, with new product launches and ongoing reimbursement progress. Long-term market penetration and payer adoption remain key…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.